No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

James Hinrichs Appointed to Board of Directors and Chairman of the Audit Committee of Outset Medical

Editor: What To Know

  • Requiring just an electrical outlet and tap water to operate, Tablo frees providers from having to rely on expensive clinic infrastructure, enabling on-demand, cost-effective dialysis in a range of use environments.
  • Outset Medical’s Tablo was designed as an enterprise solution to reduce the cost and complexity of dialysis while improving the experience for patients and providers.
  • Although more than 85 million dialysis treatments take place in the United States each year at an estimated annual cost of ~$75 billion, little meaningful technology or service model innovation has been introduced in decades.

Outset Medical CEO, Leslie Trigg said, “We are thrilled to have James Hinrichs join our Board of Directors. With a 30-year track record of both private and public company success, his governance and financial operations experience in high-growth environments will be invaluable to Outset.”

James Hinrichs has held the role of Chief Financial Officer at multiple companies including Alere Inc. until its sale to Abbott Labs, and CareFusion Corporation until its sale to Becton Dickinson. James Hinrichs also currently serves as a director of Orthofix Inc., Integer Holdings, Acutus Medical and Cibus. He holds undergraduate and graduate degrees in business from Carnegie Mellon University.

“Outset is poised for significant growth, and I’m incredibly excited to join their board,” said Mr. Hinrichs. “The expanded commercialization of Tablo will give providers much-needed innovation to reduce the cost and complexity of delivering dialysis.”

Dialysis is delivered to more than 550,000 U.S. patients several times per week to remove waste products and excess fluid from patients with kidney failure. Although more than 85 million dialysis treatments take place in the United States each year at an estimated annual cost of ~$75 billion, little meaningful technology or service model innovation has been introduced in decades.

Outset Medical’s Tablo was designed as an enterprise solution to reduce the cost and complexity of dialysis while improving the experience for patients and providers. With real-time water purification and dialysis fluid production integrated into a single, compact system, Tablo functions like a dialysis clinic on wheels. Requiring just an electrical outlet and tap water to operate, Tablo frees providers from having to rely on expensive clinic infrastructure, enabling on-demand, cost-effective dialysis in a range of use environments. Tablo was designed to look and feel like an intuitive consumer product, keeping end-user simplicity in mind. Wireless data, sensor-based automation, and an animated touchscreen make Tablo easy to learn and use for healthcare professionals and patients alike.


Other executives on the move can be found here.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy